ZAP70 Antibody

說明書

中文名稱：

ZAP70兔多克隆抗體
貨號：

CSB-PA026303GA01HU
規(guī)格：

￥3,900
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

Uniprot No.：

P43403
基因名：

ZAP70
別名：

70 kDa zeta associated protein antibody; 70 kDa zeta-associated protein antibody; EC 2.7.10.2 antibody; FLJ17670 antibody; FLJ17679 antibody; Selective T cell defect antibody; SRK antibody; STD antibody; Syk related tyrosine kinase antibody; Syk-related tyrosine kinase antibody; Truncated ZAP kinase antibody; Tyrosine protein kinase ZAP70 antibody; Tyrosine-protein kinase ZAP-70 antibody; TZK antibody; ZAP 70 antibody; ZAP70 antibody; ZAP70_HUMAN antibody; Zeta chain associated protein kinase 70kD antibody; Zeta chain associated protein kinase 70kDa antibody; Zeta chain associated protein kinase 70kDa isoform 1 antibody; Zeta chain associated protein kinase 70kDa isoform 2 antibody; Zeta chain of T cell receptor associated protein kinase 70 antibody; Zeta chain TCR associated protein kinase 70kD antibody; Zeta chain TCR associated protein kinase 70kDa antibody
宿主：

Rabbit
反應種屬：

Human,Mouse,Rat
免疫原：

Human ZAP70
免疫原種屬：

Homo sapiens (Human)
抗體亞型：

IgG
純化方式：

Antigen Affinity purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
產(chǎn)品提供形式：

Liquid
應用范圍：

ELISA,WB,IHC
Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates motility, adhesion and cytokine expression of mature T-cells, as well as thymocyte development. Contributes also to the development and activation of primary B-lymphocytes. When antigen presenting cells (APC) activate T-cell receptor (TCR), a serie of phosphorylations lead to the recruitment of ZAP70 to the doubly phosphorylated TCR component CD247/CD3Z through ITAM motif at the plasma membrane. This recruitment serves to localization to the stimulated TCR and to relieve its autoinhibited conformation. Release of ZAP70 active conformation is further stabilized by phosphorylation mediated by LCK. Subsequently, ZAP70 phosphorylates at least 2 essential adapter proteins: LAT and LCP2. In turn, a large number of signaling molecules are recruited and ultimately lead to lymphokine production, T-cell proliferation and differentiation. Furthermore, ZAP70 controls cytoskeleton modifications, adhesion and mobility of T-lymphocytes, thus ensuring correct delivery of effectors to the APC. ZAP70 is also required for TCR-CD247/CD3Z internalization and degradation through interaction with the E3 ubiquitin-protein ligase CBL and adapter proteins SLA and SLA2. Thus, ZAP70 regulates both T-cell activation switch on and switch off by modulating TCR expression at the T-cell surface. During thymocyte development, ZAP70 promotes survival and cell-cycle progression of developing thymocytes before positive selection (when cells are still CD4/CD8 double negative). Additionally, ZAP70-dependent signaling pathway may also contribute to primary B-cells formation and activation through B-cell receptor (BCR).
基因功能參考文獻：
1. ZAP-70 was a strong prognostic biomarker for patients with CLL PMID: 29680229
2. In this article, the authors have shown that Natural killer cells can reduce their functional role through downregulation of Syk and Zap70 kinases. PMID: 29263215
3. These results identify a tight negative feedback loop in which ZAP-70-activated p38 reciprocally phosphorylates ZAP-70 and destabilizes the signaling complex. PMID: 29440413
4. we have identified a new redox-active motif which is crucial for the regulation of Zap70 stability/activity. We believe that this motif has the potential to become a novel target for the development of therapeutic tools to modulate the expression/activity of kinases. PMID: 28415650
5. The expression of COBLL1, LPL, and ZAP70 corresponded to patient prognosis and to IGHV mutational status, although not absolutely. When we combined all three markers together and performed the ROC analysis, AUC increased compared to the AUC of individual gene expression. PMID: 27185377
6. The authors find that ZAP-70 selects its substrates by utilizing an electrostatic mechanism that excludes substrates with positively-charged residues and favors LAT and SLP-76 phosphosites that are surrounded by negatively-charged residues. PMID: 27700984
7. The data describe the critical early step of directional cell movement toward SDF-1 that ZAP-70 is recruited to the CXCR4 at the leading edge of membrane and consequently modulates lamellipodia/filopodia formation and integrin activation. PMID: 28846922
8. The study identified the criteria for the design of binders that specifically address either the Syk or the Zap-70 Tandem Src Homology 2 Domains, tSH2. While Syk tSH2 has a rather broad substrate scope, ZAP-70 tSH2 required a proximal arrangement of the phosphotyrosine ligands in defined strand orientation. PMID: 28767218
9. ZAP-70 signaling was impaired by cholesterol depletion, further supporting the importance of membrane organization in TCR signaling. PMID: 27384937
10. We conclude that ZAP70 plays a role for the homing to and/or the survival of ALL cells in the CNS and that ZAP70 may represent a therapeutic target. Furthermore, targeting CCR7/CXCR4 may be particularly promising in treating T-ALL. PMID: 27686375
11. The aim of this study was to evaluate the expression of ZAP70 changing during disease progression, the intracellular interferon gamma (IFN-gamma) and IL-4 content of T and B lymphocytes and the CLL cell subset (CD5+CD19+) in CLL patients and healthy subjects, and ZAP70 correlation with cytokine production. PMID: 26376785
12. in this study, authors discovered a cycle of recruitment, activation and release for Zap70 kinases at phosphorylated T-cell antigen receptors, which turned them into a 'catalytic unit' that amplified antigenic stimuli PMID: 27869819
13. The histological observations suggested that the patients represent diverse cases of NHL like mature B-cell type, mature T-cell type and high grade diffuse B-cell type NHL. The findings indicate that patients with NHL may also be analyzed for status of PAX5, CD19 and ZAP70, and their transcriptional and post-translational variants for the differential diagnosis of NHL and therapy. PMID: 27748274
14. Compound heterozygous mutations in ZAP70 gene is associated with leaky severe combined immunodeficiency disorder. PMID: 28124082
15. The results suggest that genetic polymorphism in the 3' UTR of ZAP-70 is associated with rheumatoid arthritis susceptibility in southern Taiwanese. PMID: 26245723
16. Cellular studies with ZAP70 showed that multiple lipids bind its C-terminal SH2 domain in a spatiotemporally specific manner and thereby exert exquisite spatiotemporal control over its protein binding and signaling activities in T cells. PMID: 27052731
17. Whole-exome sequencing performed on five family members revealed two affected siblings to be compound heterozygous for two unique missense mutations in the 70-kD T cell receptor zeta-chain associated protein (ZAP-70). PMID: 26783323
18. The data suggest that ZO-1, along with CD38 and Zap-70, plays a role in cell cycle regulation in chronic B cell leukemia, and may be used as a prognostic marker in the disease monitoring. PMID: 26306999
19. A distinct set of proteins interaction partners required for chemokine-directed T cell migration is attracted by phosphotyrosine 571 of ADAP, including ZAP70. PMID: 26246585
20. Activation of innate immune receptors induces an antiapoptotic signal and proliferation in ZAP-70-positive chronic lymphocytic leukemia dependent on Syk activation. PMID: 26508782
21. In all, our study demonstrates that miR-631 decreases PCa cell migration and invasion by dampening ZAP70 expression. PMID: 26620225
22. The differential requirements of ZAP70 and SYK during thymic development. PMID: 26187144
23. Blockade of CXCR7 suppressed MIF-mediated ERK- and zeta-chain-associated protein kinase (ZAP)-70 activation PMID: 26139098
24. The kinase activity of ZAP-70 stimulates negative feedback pathways that target Lck and thereby modulate the phosphorylation patterns of the immunoreceptor tyrosine-based activation motifs of t cell receptors. PMID: 25990959
25. Low ZAP-70 expression is associated with B-cell chronic lymphoid leukemia. PMID: 25743836
26. we observed decreased CD3 surface expression, reduced ZAP-70 abundance and increased histone H3-acetylation in activated T lymphocytes after 5 minutes of clinorotation and a transient downregulation of CD3 and stable downregulation of IL-2R PMID: 25661802
27. These findings confirm the role of PTPN22 and CD28 involved in the T cell activation pathway in the development of T1D in Tunisian families. Interestingly, ZAP70 and TCRbeta/CD3z seem to contribute to the susceptibility to the disease in our population. PMID: 25448703
28. In ZAP-70(+) patients with B-cell chronic lymphocytic leukaemia, the CD4/CD8 ratio was significantly below the norm indicating an active disease process. PMID: 25804237
29. ZAP-70 and CD 38 positivity were detected 25% and 36%, respectively in Chronic lymphocytic leukemia patients with concordance rate of 56%, which is higher than Western literature. PMID: 24369212
30. results provide the first evidence for differential expression of CD27 among CLL prognostic groups, suggest a role for ZAP-70 dependent signaling in CD27 induction and implicate CD27 in cell-cell interactions with the lymphoid tissue microenvironment PMID: 26002513
31. novel biosensor ROZA-XL displays a 3-4 times greater dynamic range than its predecessor and possesses a robust baseline FRET value for ZAP-70 PMID: 25735979
32. Data indicate there was substantial decline in ZAP-70 and biomarker protein levels in Vacutainer cell processing tubes (CPTs)-isolated chronic lymphocytic leukemia (CLL) cells. PMID: 25124785
33. Data indicate that the decreasing trend in the expression level of TCRzeta chain, ZAP-70 kinase and epsilon Fc Receptors FcvarepsilonRIgamma was significantly associated with disease progression. PMID: 25513989
34. A specific cysteine residue in the phosphotyrosine-binding pocket of each protein (Cys39 in ZAP-70, Cys206 in Syk) that is necessary for inhibition thiol-reactive compounds, was identified. PMID: 25287889
35. The corrected mean fluorescence intensity (CorrMFI) represents the most promising method currently available in a routine diagnostic setting for the assessment of ZAP-70 expression in CLL patients. PMID: 24127306
36. in early stage B-CLL patients, ZAP-70 upregulation is associated with distinct patterns of activation/differentiation stage subset distribution and of cytokine expression in CD4 T lymphocytes. PMID: 24166938
37. ZAP-70 CpG+223 methylation represents a superior biomarker in risk-stratification of chronic lymphocytic leukemia PMID: 24868078
38. ZAP-70 enhances the migration of malignant B-cells into the supportive microenvironment found in the bone marrow mainly by enhancing signaling and migration after CXCR4 stimulation. PMID: 24312539
39. LAT is a modulator of CD3zeta and ZAP-70 tyrosine phosphorylation. PMID: 24204825
40. Zap70 mutation reducing protein stability demonstrates rate-limiting threshold for Zap70 protein levels exists at which signalling capacity switches from nearly intact to effectively null. PMID: 24164480
41. Both drugs significantly decreased the expressions of CD5 and ZAP-70. PMID: 23686733
42. A deficient lipid rafts recruitment of CD3zeta/ZAP-70/Grb2, and these proteins do not merge with GM1 within the lipid rafts. PMID: 23916875
43. Data indicate that inflammatory cytokine-induced increases in chronic lymphocytic leukemia (CLL) cell adhesion to stromal cells are correlated with ZAP-70 expression and blocked by PI3K inhibitor. PMID: 23981382
44. investigated, using the Sequenom MassARRAY platform, polymorphisms of sixteen single-nucleotide polymorphisms (SNPs) belonging to PTPN22, CD28, CTLA-4, and ZAP-70 genes in 76 T1D patients and 162 unrelated healthy controls PMID: 24103478
45. Expression of ZAP70 in CLL cells increases expression of the NF-kappaB target genes interleukin-1beta, IL6 & IL8 upon BCR triggering. ZAP70 directly amplifies NF-kappaB signalling in CLL cells which could be an underlying mechanism for its poor prognosis. PMID: 24219331
46. ZAP70 expression in regulatory T cells in allergic rhinitis: effect of immunotherapy. PMID: 23786282
47. CBAP indeed can function as a novel signaling component within the ZAP70/Vav1/talin complex and plays an important role in regulating chemokine-promoted T-cell trafficking. PMID: 23620790
48. Evaluated expression of CD74 in chronic lymphocytic leukemia patients. CD74 expression was significantly higher in CLL group than in controls. There was positive correlation between CD74 and ZAP70 expression. PMID: 23572149
49. These results suggest the involvement of the ZAP70 and PTPN6 genes in the genetic component conferring a general susceptibility to Crohn's disease and ulcerative colitis, respectively. PMID: 23406209
50. Structural basis for activation of ZAP-70 by phosphorylation of the SH2-kinase linker.Autoinhibition of ZAP-70 is fully released upon phosphorylation by Src family kinases. PMID: 23530057
顯示更多

收起更多
相關(guān)疾病：

Immunodeficiency 48 (IMD48); Autoimmune disease, multisystem, infantile-onset, 2 (ADMIO2)
亞細胞定位：

Cytoplasm. Cell membrane; Peripheral membrane protein.
蛋白家族：

Protein kinase superfamily, Tyr protein kinase family, SYK/ZAP-70 subfamily
組織特異性：

Expressed in T- and natural killer cells. Also present in early thymocytes and pro/pre B-cells.
數(shù)據(jù)庫鏈接：

HGNC: 12858

OMIM: 176947

KEGG: hsa:7535

STRING: 9606.ENSP00000264972

UniGene: Hs.234569

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human